Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

As bad as it may look on the charts, Moderna's (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks with potential to explode in 2025. The recent pullback in US equities can be a sign of ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday morning, MarketBeat.com reports. The brokerage issued a neutral rating and ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases by the CEO and director. This comes as a significant ...

as seen in the chart below. During this timeframe, the stock also underperformed the broader Medical sector and the S&P 500. Shares of Moderna are currently trading below their 200-day and 50-day ...